Not every insulin is labeled for use with every insulin delivery device. See which insulins are indicated for use with each device under current U.S. labeling — and where a pharmacy substitution could result in a labeling mismatch between an insulin and a specific insulin pump, automated insulin delivery (AID) system, patch pump, or connected pen. Built to support prescribing, dispensing, and training conversations.
Compatibility is tied to the specific device model, not the manufacturer or brand family. An insulin labeled for one system may not be labeled for another from the same company — for example, Lyumjev is labeled for the Tandem t:slim X2 with Control-IQ+ but not for Tandem Mobi.
The devices here are intended for U-100 insulin unless otherwise noted in the specific device labeling. Concentrated insulins (U-200, U-300, U-500) should not be substituted — using a different concentration can lead to incorrect insulin delivery.
Some devices label specific branded products, biosimilars, or cartridge formats. Do not assume all insulin aspart or all insulin lispro products are interchangeable for device use — the iLet, for instance, labels Fiasp only in the prefilled PumpCart cartridge, not from a vial.
Some insulin–device combinations carry shorter wear-time limits or other use restrictions. Apidra in the Insulet Omnipod DASH, for example, is labeled for 48 hours rather than 72.
Several rapid-acting biosimilars are FDA-approved. Kirsty (insulin aspart) is an interchangeable biosimilar of NovoLog, the brand-name insulin it was developed to match. A pharmacist may substitute it without prescriber sign-off, subject to state law. The absence of a biosimilar insulin from a device's labeling does not automatically mean its use with that device is off-label — an interchangeable biosimilar can generally be used wherever the device User Guide permits its reference product. Confirm the device User Guide and the insulin's prescribing information (section 2.2) before dispensing.
Merilog (insulin aspart) and Admelog (insulin lispro) are biosimilars but are not interchangeable, so they are not auto-substituted at the pharmacy.
Insulin and device choices should weigh clinical needs, safety, cost and coverage, access, dexterity, vision, technology comfort, daily routines, and the preferences of the person using the device.